# Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

> **NCT05697861** · — · RECRUITING · sponsor: **Intellia Therapeutics** · enrollment: 72 (estimated)

## Conditions studied

- Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
- Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
- Wild-Type Transthyretin Cardiac Amyloidosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05697861
- **Lead sponsor:** Intellia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-10
- **Primary completion:** 2038-03
- **Final completion:** 2038-03
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05697861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05697861, "Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05697861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*